Anxiolytic compounds

1. A method for treating anxiety associated with autism spectrum disorders (ASD) in children, the method comprising administering to a patient in need thereof a compound of formula (If), or a pharmaceutically acceptable salt thereof:

wherein X represents O or NR″;

R″ is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted acyl, optionally substituted alkenyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted oxysulfinyl, optionally substituted oxysulfonyl, optionally substituted sulfinyl, and optionally substituted sulfonyl;

Y represents OR′″ or NR 3 R 4 ;

R′″ is H or optionally substituted alkyl;

R represents H or optionally substituted alkyl;

R 1 represents optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;

R 2 represents H, optionally substituted cycloalkyl, optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted alkenyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted oxysulfinyl, optionally substituted oxysulfonyl, optionally substituted sulfinyl, or optionally substituted sulfonyl;

R 3 and R 4 each independently represent optionally substituted alkyl, or wherein NR 3 R 4 forms an optionally substituted N-containing heteroaryl or optionally substituted N-containing heterocyclyl; and

each R′ is independently selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, optionally substituted alkyl, optionally substituted acyl, alkoxy, optionally substituted aryl, oxyacyl, acyloxy, optionally substituted arylalkyl, optionally substituted sulfinyl, optionally substituted sulfonyl, oxyacylamino, oxythioacyl, thioacyloxy, optionally substituted sulphinylamino, optionally substituted amino, optionally substituted sulphonylamino, optionally substituted thio, oxysulfinylamino, oxysulfonylamino, optionally substituted alkenyl, and optionally substituted alkynyl.

2. The method according to claim 1 , wherein each R′ is hydrogen.

3. The method according to claim 1 , wherein X is NR″; and

R″ is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted acyl, optionally substituted alkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted oxysulfinyl, optionally substituted oxysulfonyl, optionally substituted sulfinyl, and optionally substituted sulfonyl.

4. The method according to claim 1 , wherein Y is NR 3 R 4 , and NR 3 R 4 forms an optionally substituted N-containing heteroaryl or optionally substituted N-containing heterocyclyl.

5. The method according to claim 1 , wherein R 1 is an optionally substituted cycloalkyl or optionally substituted cycloalkenyl.

6. The method according to claim 1 , wherein R 1 is a benzofused C 5 -C 7 cycloalkyl; wherein the benzene ring may be optionally substituted.

7. The method according to claim 1 , wherein the compound of formula (If) is:

or a pharmaceutically acceptable salt thereof.

8. The method according to claim 1 , wherein the anxiety associated with autism spectrum disorders (ASD) in children is selected from the group consisting of social anxiety disorder, generalized anxiety disorder, separation anxiety disorder, and obsessive compulsive disorder.

9. The method according to claim 7 , wherein the anxiety associated with autism spectrum disorders (ASD) in children is selected from the group consisting of social anxiety disorder, generalized anxiety disorder, separation anxiety disorder and obsessive compulsive disorder.